Posted on

Diabetes Projected to Affect 1.3 Billion People by 2050

Loading

— Advance of disease driven by high BMI, with social determinants of health playing a role

By Elizabeth Short

SAN DIEGO — The total number of people living with diabetes worldwide is expected to more than double over the next 30 years, reported researchers of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021.

Based on data from 204 countries and territories, approximately 529 million were estimated to be living with diabetes across the world in 2021, a number projected to grow to over 1.31 billion by 2050, according to Kanyin Liane Ong, PhD, of the University of Washington in Seattle, and colleagues of the GBD 2021 Diabetes Collaborators. Read more in MedPage Today.

Loading
Posted on

Risk Factors for Venous Thromboembolism in Kidney Transplant Recipients Identified

Loading

By Natasha Persaud

Certain kidney transplant recipients, such as those with anemia, have increased risks of venous thromboembolism, investigators reported at the 2023 American Transplant Congress in San Diego, California.

Investigators matched 65 recipients at their institution who experienced venous thromboembolism with 65 recipients who did not by age and year of transplantation. Median patient age at transplantation was 54 years. Read the full article in Clinical Pain Advisory.

Loading
Posted on

Should Transplant Recipients Have Pets?

Loading

Alex Harrison-Flaxman is a kidney transplant recipient who understands the rollercoaster of emotions that patients face after transplant.

“Being a transplant recipient is an absolute blessing, but it doesn’t come without its challenges,” says Harrison-Flaxman. “It’s a constant battle to stay vigilant and be on top of your care. But having my dog Bendel makes it a little more bearable when my anxiety is high, and the road ahead seems impossible.” Read the full article on CareDx.com.

Loading
Posted on

Race-neutral testing could have given access to life-saving lung transplants for more black patients

Loading

Peer-Reviewed Publication

June 21, 2023 – NEW YORK, NY— Race-neutral lung function interpretation could increase access to lung transplants for Black patients with respiratory disease, according to new research published in the Annals of the American Thoracic Society online ahead of print.

In “Race-Specific Interpretation of Spirometry: Impact on the Lung Allocation Score,” lead researcher J. Henry Brems, MD, MBE of the Johns Hopkins School of Medicine, and colleagues investigated how race-specific versus race-neutral equations alter the lung allocation score (LAS) and the priority for lung transplant across races. The lung allocation score determines which patients get priority on the lung transplant listing.
Read the full article from the American Thoracic Society.

Loading
Posted on

VCU researchers want to develop better tools to help diagnose millions of patients with liver disease

Loading

The study is funded by a $2.87 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases.

By A.J. Hostetler

Researchers at the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University hope a new five-year study will help them develop better diagnostic tools for patients with an aggressive liver disease that is a leading cause for liver transplantation.

In patients suffering from metabolic dysfunction-associated steatotic liver disease (MASH, formerly called NASH), a build-up of fat in the liver damages cells and causes inflammation.
Read the full article in the VCUHealth News Center.

Loading
Posted on

Las Vegas man spreads awareness with story of life-saving liver transplant

Loading

By Shawna Khalafi

LAS VEGAS, Nev. (FOX5) – In recognition of Father’s Day and Men’s Health Week, a Las Vegas dad is sharing his story of a life-saving organ transplant, in order to spread awareness and inspire other men to take their health seriously.

“My son and my wife had to rush me to Mountain View Hospital here in Las Vegas, and within 48 hours during that July 4th weekend, I found out that I had less than 30 days to live because I had end life liver failure,” said Angelo Reyes. Read the full story from KVVU-TV Fox 5 News in Las Vegas.

Loading
Posted on

Six-Month Survival Following Heart Transplant After Donor Circulatory Death Is Noninferior to Transplant After Donor Brain Death

Loading

By Luke Halpern

Notably, donor hearts from those who underwent circulatory death were able to be preserved and analyzed in situ.

Survival at 6 months after transplantation with a donor heart that was reanimated and assessed after circulatory-death was found to be noninferior to patient survival among recipients of the standard care transplantation using a donor heart that had been preserved in cold storage after brain-death, according to the results of a new study published in The New England Journal of Medicine. The more in Pharmacy Times.

Loading
Posted on

Study finds race-neutral testing could have provided access to life-saving lung transplants for more Black patients

Loading

By American Thoracic Society

Race-neutral lung function interpretation could increase access to lung transplants for Black patients with respiratory disease, according to new research published in the Annals of the American Thoracic Society online ahead of print.

In “Race-Specific Interpretation of Spirometry: Impact on the Lung Allocation Score,” lead researcher J. Henry Brems, MD, MBE, of the Johns Hopkins School of Medicine, and colleagues investigated how race-specific versus race-neutral equations alter the lung allocation score (LAS) and the priority for lung transplant across races. Read the full article in Medical Xpress.

Loading
Posted on

New Antiviral Option for CMV Prophylaxis After Kidney Transplant

Loading

— Letermovir proved noninferior to standard of care in clinical trial

By Jeff Minerd

Letermovir (Prevymis) proved noninferior to valganciclovir (Valcyte), the standard of care, in a clinical trial of cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients, researchers reported.

In a phase III trialopens in a new tab or window of 589 patients randomized 1:1 to receive either drug for up to 200 days post-transplant, the prevalence of CMV disease at 1 year was not significantly different in the letermovir group versus the valganciclovir group (10.4% vs 11.8%, adjusted difference -1.4%, 95% CI -6.5% to 3.8%), reported Ajit Limaye, MD, of the University of Washington Medicine in Seattle, and colleagues.
Read the full article in MedPage Today.

Loading